Vietnam Healthcare Diagnostics & Imaging Market Size, Share & Forecast, 2026-2031

The Vietnam Healthcare Diagnostics & Imaging Market was worth USD 1.50 billion in 2025. The estimate covers diagnostic laboratory services, medical imaging procedures, equipment, reagents, consumables, maintenance and diagnostic informatics while removing duplicated distributor resale value. Supply-side company revenue, operational procedure economics and demand-side utilization produced estimates of USD 1.47 billion, USD 1.53 billion and USD 1.50 billion respectively. Their weighted result was rounded to the published base value.

The market is forecast to reach USD 2.42 billion by 2031, representing an 8.30% CAGR from the 2025 base. Diagnostic procedure volume increases from 150 million to 215 million equivalents, while blended revenue per procedure rises from USD 10.00 to USD 11.26. Growth therefore combines higher utilization with a mix shift toward molecular testing, advanced imaging, software, AI-supported workflows and recurring lifecycle contracts.

Profit pools will shift toward recurring reagents, molecular assays, high-complexity imaging, diagnostic software and managed-service contracts. Conventional equipment will remain essential, but standalone capital sales face tender pressure and irregular replacement cycles. Reagent-rental agreements and service contracts create stronger revenue visibility, while AI-enabled interpretation and digital pathology improve throughput without requiring proportional specialist headcount growth. Molecular testing also supports premium pricing in oncology, infectious disease and reproductive health.

Import dependence is the most significant structural constraint because approximately 90% of medical equipment is sourced internationally. Providers face currency exposure, registration complexity, spare-parts delays and service-engineer availability, while advanced imaging systems require substantial capital. Regulatory changes also demand ongoing technical-file and classification updates. Smaller provincial providers can therefore struggle to acquire and maintain equipment even when underlying patient demand is strong.

Vietnam ranks fourth among the selected peer markets by 2025 value, behind Indonesia, Thailand and Malaysia but ahead of the Philippines. Its estimated 8.30% CAGR exceeds Thailand's 6.40% and Malaysia's 7.10%, reflecting lower current penetration and stronger catch-up investment. Vietnam also combines a large population with insurance coverage above 95%, although per-capita health spending remains below Malaysia and Thailand.

The combination of near-universal health insurance and a high noncommunicable-disease burden has the greatest influence. Vietnam recorded 195.5 million insured-care visits in 2025, while noncommunicable diseases account for approximately 80% of deaths. Cardiovascular disease, diabetes, cancer and neurological conditions require repeated testing and imaging rather than one-time diagnosis. Aging further increases utilization intensity across public hospitals, private facilities and independent laboratories.

Successful entry requires regulatory registration, public-tender expertise, trusted distributors, clinical application support, service engineering and flexible financing. Equipment suppliers must demonstrate uptime, training and local spare-parts availability, while diagnostic companies need reliable reagent supply and quality-control support. Partnerships with hospital chains, reference laboratories and provincial distributors can accelerate access, but commercial contracts should protect pricing, service standards, data ownership and minimum purchase commitments.